Browse result page of AntiTbPdb
The total number entries retrieved from this search are 262
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1246 | (LLKK)2M | LLKKLLKKM | Free | Free | None | Linear | 9 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis CSU87 reistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin | MIC = 125 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1247 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis (ATCC No. 14468) | MIC = 62.5 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1248 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis (ATCC No. 14468) | MIC = 15.6 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | Rifampicin, shows synergy | Antibacterial | 2014 | 24314557 |
| antitb_1249 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis resistant agianst rifampicin | MIC = 62.5 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1250 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis resistant agianst rifampicin | MIC = 15.6 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | Rifampicin, shows synergy | Antibacterial | 2014 | 24314557 |
| antitb_1251 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG lux | MIC = 15.6 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1252 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG lux | MIC = 3.91 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | Rifampicin, shows synergy | Antibacterial | 2014 | 24314557 |
| antitb_1253 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 125 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1254 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 7.81 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | Rifampicin, shows synergy | Antibacterial | 2014 | 24314557 |
| antitb_1255 | M(LLKK)2M | MLLKKLLKKM | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis CSU87 reistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin | MIC = 62.5 mg/L | In vitro | Rat red blood cells (rRBCs) | NA | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L | None | NA | NA | Membrane-lytic mechanism | Cell envelope | None | Antibacterial | 2014 | 24314557 |
| antitb_1268 | VapB30 (52-59) | ELAAIRHR | Free | Free | None | Linear | 8 | L | NA | Protein Derived | From VapB30 toxin | Mycobacterium tuberculosis | Mycobacterium tuberculosis (strain H37Rv) | NA | NA | NA | NA | NA | None | NA | NA | By disrupting the toxin-antitoxin complex (VapBC) | VapBC | None | NA | 2015 | 26150422 |
| antitb_1270 | VapC30 (48-56) | RFGEPGGRE | Free | Free | None | Linear | 9 | L | NA | Protein Derived | From VapC30 toxin | Mycobacterium tuberculosis | Mycobacterium tuberculosis (strain H37Rv) | NA | NA | NA | NA | NA | None | NA | NA | By disrupting the toxin-antitoxin complex (VapBC) | VapBC | None | NA | 2015 | 26150422 |
| antitb_1293 | Trichoderins A | (MDA)-P-(AHMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC = 0.1 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1294 | Trichoderins A | (MDA)-P-(AHMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium bovis | Mycobacterium bovis BCG | MIC =0.02 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1295 | Trichoderins A | (MDA)-P-(AHMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 0.12 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1296 | Trichoderins A1 | (MDA)-P-(AMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AMOD = 2-amino-4-methy1-8-oxodec-6-enoic acid, Aib = a-amino- isobutyric acid, | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC = 1.56 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1297 | Trichoderins A1 | (MDA)-P-(AMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AMOD = 2-amino-4-methy1-8-oxodec-6-enoic acid, Aib = a-amino- isobutyric acid, | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 0.16 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1298 | Trichoderins A1 | (MDA)-P-(AMOD)-(Aib)-(Aib)-I-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AMOD = 2-amino-4-methy1-8-oxodec-6-enoic acid, Aib = a-amino- isobutyric acid, | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 2.0 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1299 | Trichoderins B | (MDA)-P-(AHMOD)-(Aib)-(Aib)-V-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC =0.63 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2010 | 20483615 |
| antitb_1300 | Trichoderins B | (MDA)-P-(AHMOD)-(Aib)-(Aib)-V-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 0.02 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2011 | 20483615 |
| antitb_1301 | Trichoderins B | (MDA)-P-(AHMOD)-(Aib)-(Aib)-V-V-(Aib)-(Aib)-(AMAE) | Addition of MDA = 2-methyl decanoic acid. | Addition of AMAE = 2-[(20-aminopropyl) methylamino] ethanol. | AHMOD = 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid, Aib = α-amino- isobutyric acid | Linear | 8 | L | NA | Natural | Isolated from a culture of marine sponge derived fungus of Trichoderma sp. | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 0.13 μg/mL | In vitro | None | NA | NA | None | NA | NA | NA | NA | None | None | 2012 | 20483615 |
| antitb_1330 | Human beta casein fragment (54-59) | VEPIPY | Free | Free | None | Linear | 6 | L | Cationic | Protein derived | Human beta casein protein | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 25μM | in vitro | THP 1 cell lines | Cells treated with 10 mM and 20 mM peptide showed 17.13% and 29.56% increase in clearance of BCG | NA | NA | NA | Increase expression of IL-8, MCP-1, MIP-1β, TNF-α | NA | NA | NA | NA | 2012 | 23029305 |
| antitb_1349 | Tenecin 1 Fragment 33-43 | YCNGKRVCVC | Free | Amidation | Internal disulphide bond | Cyclic | 10 | NA | NA | Natural | Larvae of tenebrio molitor(beetle) | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC 612 | MIC = >100 μg/ml | in vitro | Human erythrocyte | NA | None | NA | NA | NA | Membrane disruption as reported by membrane leaky assay | NA | NA | Antibacterial against MRSA, bacillus subtilis, E.coli, Shigella at 10-30 μg/ml | 1998 | 9693108 |
| antitb_1351 | Tenecin 1 Fragment 35-43 | CNGKRVCVCR | Free | Amidation | None | Linear | 10 | NA | NA | Natural | Larvae of tenebrio molitor(beetle) | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC 614 | MIC = >100 μg/ml | in vitro | Human erythrocyte | NA | None | NA | NA | NA | Membrane disruption as reported by membrane leaky assay | NA | NA | None | 1998 | 9693108 |
| antitb_1352 | Tenecin 1 Fragment 34-42 | NGKRVCVCR | Free | Amidation | None | Linear | 9 | NA | NA | Natural | Larvae of tenebrio molitor(beetle) | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC 615 | MIC = >100 μg/ml | in vitro | Human erythrocyte | NA | None | NA | NA | NA | NA | NA | NA | None | 1998 | 9693108 |
| antitb_1353 | Peptide KSl | KKVVFKVKFK | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC 607 | MIC = 6.25μg/ml | In vitro | Mouse erythrocyte | NA | None | NA | NA | NA | NA | NA | NA | antifungal, antibacterial against C.albicans | 1998 | 9756752 |
| antitb_1439 | A2-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1440 | A2-TB10.4 | AMLGHAGDM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1441 | A2-TB10.4 | MLGHAGDMA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1442 | A2-Ag85B | YLLDGLRAQ | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1443 | A2-Ag85B | KLVANNTRL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1444 | A2-Ag85B | FIYAGSLSA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1445 | A2-ESAT6 | AMASTEGNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1446 | A2-ESAT | LLDEGKQSL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1447 | A2-Rv2958 | ALADLPVTV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1448 | A2-Rv2957 | SIIIPTLNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1449 | A2-Rv0447 | VLAGSVDEL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1450 | A24-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1451 | A24-Ag85B | WYYQSGLSI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1452 | A24-Ag85B | FLTSELPQW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1453 | A24-Ag85B | IYAGSLSAL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1454 | A24-ESAT6 | AYQGVQQKW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1455 | A24-ESAT6 | ELNNALQNL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1456 | A24-Rv2958 | KYIAADRKI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1457 | A24-Rv2957 | PYNLRYRVL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1458 | A24-Rv0447 | KYIFPGGLL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1459 | A3001-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1460 | A3001-TB10.4 | LVRAYHAMS | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1461 | A3001-Rv2957 | IVLVRRWPK | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2957 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2957 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1462 | A3002-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |